UroGen Pharma, which is developing gel-based chemotherapies to treat urological cancers, raised $58 million by offering 4.5 million shares at $13, within the range of $12 to $14. . It originally planned to offer 3.5 million shares and raised 29% more in proceeds. UroGen Pharma plans to list on the Nasdaq under the symbol URGN. Jefferies and Cowen & Company acted as lead managers on the deal.
